Atara Biotherapeutics Q3 revenue beats estimates as costs decline
ATRA•Atara Biotherapeutics reported Q3 revenue of $1.22 million, above the $666,670 analyst estimate, and a net loss of $2.23 million. The company expects operating expenses to decline significantly year over year in 2026 and says cash and investments should fund operations into mid-2027.
1. Revenue and costs
Atara Biotherapeutics’ Q3 revenue fell year over year but exceeded analyst expectations. The company said the decline was primarily due to a one-time sale of clinical inventory in the prior-year quarter. Net loss narrowed to $2.23 million, while operating loss was $2.97 million and loss per share was $0.15.
2. Outlook and FDA date
Operating expenses declined sharply, which the company attributed to cost-reduction initiatives implemented in 2025 and early 2026. Atara expects operating expenses to decline significantly year over year in 2026 and anticipates cash and investments will fund operations into mid-2027. The FDA set March 31, 2027, as the target action date for the tab-cel BLA.
